Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Kidney Int ; 103(3): 565-579, 2023 03.
Artigo em Inglês | MEDLINE | ID: mdl-36442540

RESUMO

The diagnosis of nephrotic syndrome relies on clinical presentation and descriptive patterns of injury on kidney biopsies, but not specific to underlying pathobiology. Consequently, there are variable rates of progression and response to therapy within diagnoses. Here, an unbiased transcriptomic-driven approach was used to identify molecular pathways which are shared by subgroups of patients with either minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS). Kidney tissue transcriptomic profile-based clustering identified three patient subgroups with shared molecular signatures across independent, North American, European, and African cohorts. One subgroup had significantly greater disease progression (Hazard Ratio 5.2) which persisted after adjusting for diagnosis and clinical measures (Hazard Ratio 3.8). Inclusion in this subgroup was retained even when clustering was limited to those with less than 25% interstitial fibrosis. The molecular profile of this subgroup was largely consistent with tumor necrosis factor (TNF) pathway activation. Two TNF pathway urine markers were identified, tissue inhibitor of metalloproteinases-1 (TIMP-1) and monocyte chemoattractant protein-1 (MCP-1), that could be used to predict an individual's TNF pathway activation score. Kidney organoids and single-nucleus RNA-sequencing of participant kidney biopsies, validated TNF-dependent increases in pathway activation score, transcript and protein levels of TIMP-1 and MCP-1, in resident kidney cells. Thus, molecular profiling identified a subgroup of patients with either MCD or FSGS who shared kidney TNF pathway activation and poor outcomes. A clinical trial testing targeted therapies in patients selected using urinary markers of TNF pathway activation is ongoing.


Assuntos
Glomerulosclerose Segmentar e Focal , Nefrologia , Nefrose Lipoide , Síndrome Nefrótica , Humanos , Glomerulosclerose Segmentar e Focal/patologia , Nefrose Lipoide/diagnóstico , Inibidor Tecidual de Metaloproteinase-1 , Síndrome Nefrótica/diagnóstico , Fatores de Necrose Tumoral/uso terapêutico
2.
J Consum Aff ; 56(1): 141-157, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35603321

RESUMO

The Coronavirus (COVID-19) pandemic reduced real and perceived access to healthcare services, exacerbating pandemic fear, and thus influencing consumers' adoption of preventative health behaviors. Extending the EHBM, results from two studies show that perceived access to health services and pandemic fear impact an individual's general and COVID-preventative health behaviors. High perceived access reduces pandemic fear through its buffering effects on perceived health vulnerability and pandemic-related health system concern, especially with telehealth usage during the pandemic. While pandemic fear motivates COVID-19 vaccination, pandemic fear reduces personal preventative health behavior (e.g., healthy eating, exercising) and has little effect on personal COVID-preventative behaviors (e.g., wearing a mask, social distancing) when individuals perceive high pandemic-related control. Moreover, the fear-behavior link does not hold for preventative health visits; instead, perceived access directly promotes preventative visits and screening. This research informs public health stakeholders' communication, education, and resource allocation during health crises like the COVID-19 pandemic.

3.
Diabetes ; 71(12): 2664-2676, 2022 12 01.
Artigo em Inglês | MEDLINE | ID: mdl-36331122

RESUMO

Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease (ESKD). Prognostic biomarkers reflective of underlying molecular mechanisms are critically needed for effective management of DKD. A three-marker panel was derived from a proteomics analysis of plasma samples by an unbiased machine learning approach from participants (N = 58) in the Clinical Phenotyping and Resource Biobank study. In combination with standard clinical parameters, this panel improved prediction of the composite outcome of ESKD or a 40% decline in glomerular filtration rate. The panel was validated in an independent group (N = 68), who also had kidney transcriptomic profiles. One marker, plasma angiopoietin 2 (ANGPT2), was significantly associated with outcomes in cohorts from the Cardiovascular Health Study (N = 3,183) and the Chinese Cohort Study of Chronic Kidney Disease (N = 210). Glomerular transcriptional angiopoietin/Tie (ANG-TIE) pathway scores, derived from the expression of 154 ANG-TIE signaling mediators, correlated positively with plasma ANGPT2 levels and kidney outcomes. Higher receptor expression in glomeruli and higher ANG-TIE pathway scores in endothelial cells corroborated potential functional effects in the kidney from elevated plasma ANGPT2 levels. Our work suggests that ANGPT2 is a promising prognostic endothelial biomarker with likely functional impact on glomerular pathogenesis in DKD.


Assuntos
Diabetes Mellitus , Nefropatias Diabéticas , Falência Renal Crônica , Humanos , Angiopoietina-1/genética , Receptor TIE-2/genética , Nefropatias Diabéticas/genética , Estudos de Coortes , Células Endoteliais , Angiopoietina-2/genética , Angiopoietinas , Transdução de Sinais , Biomarcadores , Progressão da Doença
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA